Pilot Study of Neuromodulation for Enhancement of Emotion Regulation in Bipolar Mood Disorders
Primary Purpose
Bipolar Disorder, Transcranial Magnetic Stimulation
Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Transcranial Magnetic Stimulation (TMS)
Sponsored by
About this trial
This is an interventional health services research trial for Bipolar Disorder
Eligibility Criteria
Inclusion Criteria:
Patients
- Men and women
- Ages 18-50 years
- Patients diagnosed with bipolar I disorder (BD-I), current mood state euthymic.
- On a stable psychiatric medication regimen for at least a month prior to and during study participation
Healthy Controls:
- Men and women
- Ages 18-50 years
- Without major psychiatric illness
Exclusion Criteria:
Patients
- Any change in psychiatric medications within a month prior to and during study participation
- Legal or mental incompetency
- Intellectual disability
- Current manic (YMRS > 12) or severe depressive episode (HAM-D-17 > 5)
- Substance use disorder (abuse or dependence) with active use within the last 3 months
- Significant medical or neurological illness
- Prior neurosurgical procedure
- History of seizures
- History of ECT treatment or clinical TMS within the past three months
- Implanted cardiac pacemakers
Patients who have conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head or neck, or are non-removable and within 30 cm of the treatment coil. These include:
- Aneurysm clips or coils
- Carotid or cerebral stents
- Metallic devices implanted in the head (e.g. Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, or ventriculo-peritoneal shunt)
- Magnetically active dental implants
- Cochlear/otologic implants
- CSF shunts
- Ferromagnetic ocular implants
- Pellets, bullets, fragments less than 30 cm from the coil
- Facial tattoos with metallic ink, permanent makeup less than 30 cm from the coil
- Pregnant women
Healthy Controls:
- History of major psychiatric illness, including psychosis
- Has a first-degree relative with psychosis
- Active use of neuropsychoactive medications
- Legal or mental incompetency
- Intellectual disability
- Substance use disorder (abuse or dependence) with active use within the last 3 months
- Significant medical or neurological illness
- Prior neurosurgical procedure
- History of seizures
- History of ECT treatment or clinical TMS within the past three months
- Implanted cardiac pacemakers
Individuals who have conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head or neck, or are non-removable and within 30 cm of the treatment coil. These include:
- Aneurysm clips or coils
- Carotid or cerebral stents
- Metallic devices implanted in the head (e.g. Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, or ventriculo-peritoneal shunt)
- Magnetically active dental implants
- Cochlear/otologic implants
- CSF shunts
- Ferromagnetic ocular implants
- Pellets, bullets, fragments less than 30 cm from the coil
- Facial tattoos with metallic ink, permanent makeup less than 30 cm from the coil
- Pregnant women
Sites / Locations
- Martinos Center for Biomedical Imaging
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
Patients
Controls
Arm Description
Individuals with Bipolar 1 Disorder
Healthy controls
Outcomes
Primary Outcome Measures
Change Emotion Conflict Resolution Task
Slope of reaction time (milliseconds)
Change Cognitive Reappraisal Task
Distress rating (scale 1- 4)
Secondary Outcome Measures
Full Information
NCT ID
NCT03622749
First Posted
July 11, 2018
Last Updated
October 5, 2023
Sponsor
Massachusetts General Hospital
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
1. Study Identification
Unique Protocol Identification Number
NCT03622749
Brief Title
Pilot Study of Neuromodulation for Enhancement of Emotion Regulation in Bipolar Mood Disorders
Official Title
Pilot Study of Neuromodulation for Enhancement of Emotion Regulation in Bipolar Mood Disorders
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 1, 2019 (Actual)
Primary Completion Date
August 1, 2023 (Actual)
Study Completion Date
December 1, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The investigators are conducting this research study to better understand how individuals with bipolar disorder regulate their emotions, and if the study can use a technique called "transcranial magnetic stimulation" or TMS to help improve emotion regulation for individuals with bipolar disorder.
Detailed Description
Emotion dysregulation contributes to the development and maintenance of a wide range of psychopathology, but is especially relevant for individuals with bipolar mood disorders (BD). These individuals experience severe and episodic emotion dysregulation associated with maladaptive functioning, interpersonal problems, decreased work productivity, and suicidal ideation and behavior. To date, both pharmacological and psychosocial treatments fail to normalize emotion dysregulation for many bipolar patients. As a consequence, all too many experience poor outcomes. Thus, there is a significant need for new innovative approaches to target and improve emotion dysregulation in bipolar patients. Non-invasive neuromodulation using transcranial magnetic stimulation (TMS) may provide a viable strategy to help improve emotion dysregulation in bipolar mood disorders. As a first step to test this hypothesis, the current proposal seeks to experimentally identify specific neural target sites for improving emotion regulation using TMS. If the investigators can demonstrate target engagement of emotion regulation at the behavioral level using TMS, this will provide an important first step towards examining the potential utility of TMS as a viable strategy to help improve emotion dysregulation in bipolar mood disorders. While this is not a definitive clinical trial, the sham-controlled double-crossover design of this study will provide valuable information for target site selection for the development of TMS as an intervention strategy to improve emotion dysregulation in BD.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bipolar Disorder, Transcranial Magnetic Stimulation
7. Study Design
Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
Participant
Allocation
Randomized
Enrollment
15 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Patients
Arm Type
Active Comparator
Arm Description
Individuals with Bipolar 1 Disorder
Arm Title
Controls
Arm Type
No Intervention
Arm Description
Healthy controls
Intervention Type
Device
Intervention Name(s)
Transcranial Magnetic Stimulation (TMS)
Intervention Description
Non-Invasive neuromodulation
Primary Outcome Measure Information:
Title
Change Emotion Conflict Resolution Task
Description
Slope of reaction time (milliseconds)
Time Frame
Change from baseline to 15 minutes post-TMS stimulation
Title
Change Cognitive Reappraisal Task
Description
Distress rating (scale 1- 4)
Time Frame
Change from baseline to 15 minutes post-TMS stimulation
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patients
Men and women
Ages 18-50 years
Patients diagnosed with bipolar I disorder (BD-I), current mood state euthymic.
On a stable psychiatric medication regimen for at least a month prior to and during study participation
Healthy Controls:
Men and women
Ages 18-50 years
Without major psychiatric illness
Exclusion Criteria:
Patients
Any change in psychiatric medications within a month prior to and during study participation
Legal or mental incompetency
Intellectual disability
Current manic (YMRS > 12) or severe depressive episode (HAM-D-17 > 5)
Substance use disorder (abuse or dependence) with active use within the last 3 months
Significant medical or neurological illness
Prior neurosurgical procedure
History of seizures
History of ECT treatment or clinical TMS within the past three months
Implanted cardiac pacemakers
Patients who have conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head or neck, or are non-removable and within 30 cm of the treatment coil. These include:
Aneurysm clips or coils
Carotid or cerebral stents
Metallic devices implanted in the head (e.g. Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, or ventriculo-peritoneal shunt)
Magnetically active dental implants
Cochlear/otologic implants
CSF shunts
Ferromagnetic ocular implants
Pellets, bullets, fragments less than 30 cm from the coil
Facial tattoos with metallic ink, permanent makeup less than 30 cm from the coil
Pregnant women
Healthy Controls:
History of major psychiatric illness, including psychosis
Has a first-degree relative with psychosis
Active use of neuropsychoactive medications
Legal or mental incompetency
Intellectual disability
Substance use disorder (abuse or dependence) with active use within the last 3 months
Significant medical or neurological illness
Prior neurosurgical procedure
History of seizures
History of ECT treatment or clinical TMS within the past three months
Implanted cardiac pacemakers
Individuals who have conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head or neck, or are non-removable and within 30 cm of the treatment coil. These include:
Aneurysm clips or coils
Carotid or cerebral stents
Metallic devices implanted in the head (e.g. Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, or ventriculo-peritoneal shunt)
Magnetically active dental implants
Cochlear/otologic implants
CSF shunts
Ferromagnetic ocular implants
Pellets, bullets, fragments less than 30 cm from the coil
Facial tattoos with metallic ink, permanent makeup less than 30 cm from the coil
Pregnant women
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kristen K Ellard, PhD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Martinos Center for Biomedical Imaging
City
Charlestown
State/Province
Massachusetts
ZIP/Postal Code
02129
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Pilot Study of Neuromodulation for Enhancement of Emotion Regulation in Bipolar Mood Disorders
We'll reach out to this number within 24 hrs